GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications , as researchers learn more about how the drugs affect the body beyond just weight loss.

But one of the more anticipated studies exploring how they impact Alzheimer’s disease has found no meaningful effect, Novo Nordisk said in a press release on Nov. 24

The company, which makes semaglutide (sold as Wegovy for weight loss and Ozempic for diabetes), said that its drug did not provide any additional benefit over placebo in two trials of people with early Alzheimer’s. The company is planning to release more data at a presentation at the Clinical Trials on Alzheimer’s Disease conference in early December and at the Alzheimer’s and Parkinson’s Diseases conferences in March 2026.

The two-year study inclu

See Full Page